Opinion

Video

Private Label Biosimilars

Author(s):

Sophia Humphreys, PharmD, MHA, BCBBS,Chad Cannon, PharmD, BCCCP

The expert panel discusses the greater potential for private label biosimilars.

Video content above is prompted by the following questions:

  • Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Related Content
FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
March 4th 2025

FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

Cameron Santoro
The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations.
managed care cast banner
August 17th 2022

How Health Care Institutions Can Leverage Biosimilars to Generate Savings

Skylar Jeremias
On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Osteoporosis. | Image Credit: Nisit - stock.adobe.com
February 18th 2025

Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

Cameron Santoro
The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss, and other endocrine diseases.
Managed Care Cast
June 14th 2022

Biosimilar Whisky? This Expert Says It’s Doable, No Aging Required

On this episode of Managed Care Cast, we’re highlighting a hobby from a biosimilar expert who says he can make whisky more accessible and affordable through—you guessed it—his own biosimilar whisky.
FDA approved. | Image Credit: Olivier Le Moal - stock.adobe.com
January 31st 2025

FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra

Cameron Santoro
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
Kirollos Hanna, PharmD
January 29th 2025

Embracing EOM, Enhancing Collaboration and Cost Management: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD
The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo